Sabby Management’s TherapeuticsMD TXMD Stock Holding History

Sabby Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,500	Closed	-$744K	–	202
2021 Q2	$744K	Sell	12,500 -3,500	-22%	-$212K	0.1%	92
2021 Q1	$1.07M	Buy	+16,000	New	+$1.25M	0.21%	77
2017 Q1	–	Sell	-499	Closed	-$154K	–	316
2016 Q4	$144K	Sell	499 -182	-27%	-$56.4K	0.01%	257
2016 Q3	$232K	Buy	+681	New	+$249K	0.01%	268
2016 Q2	–	Sell	-2,608	Closed	-$1.07M	–	330
2016 Q1	$835K	Buy	+2,608	New	+$890K	0.04%	170
2015 Q2	–	Sell	-1,665	Closed	-$587K	–	359
2015 Q1	$504K	Sell	1,665 -9,332	-85%	-$2.28M	0.02%	233
2014 Q4	$2.45K	Buy	+10,997	New	+$2.27M	0.08%	110
2013 Q3	–	Sell	-6,232	Closed	-$944K	–	222
2013 Q2	$944K	Buy	+6,232	New	+$854K	0.06%	121

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's TXMD Position: Q3 2021 in Review

Sabby Management sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 12,500 shares — an estimated $744K sold.

Sabby Management first reported a position in TXMD in Q2 2013 and held it in 8 quarters. The position peaked at $1.07M in Q1 2021. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

Sabby Management reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
Sabby Management sold 12,500 TherapeuticsMD shares in Q3 2021, an estimated $744K.
Sabby Management first reported a position in TherapeuticsMD in Q2 2013 and held it in 8 quarters.
Sabby Management's TherapeuticsMD position peaked at $1.07M in Q1 2021.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.